TRDA at a glance
Entrada Therapeutics, Inc. (TRDA, SEC CIK 1689375) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as September 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Entrada Therapeutics, Inc. (TRDA) reported revenue of $25.4 million (down 87.9% from FY2024) and a net loss of $143.8 million. Diluted EPS was -$3.47.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Entrada Therapeutics, Inc. (TRDA) shares worth $80.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by MPM BioVentures 2014, L.P. on September 9, 2026 of 28,837 shares at $7.13 per share.
- In the last 90 days, TRDA insiders reported 0 open-market purchases ($0) and 33 open-market sales ($10.3M) on Form 4, a net sale of $10.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $25.4M
- −87.9% vs prior year
- Insiders · 90 days
- 0 buys · 33 sells
- Net −$10.3M
- 13F holders
- 25 funds
- $80.8M · −1 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Cash, equivalents and marketable securities $223.0M as of June 30, 2026
- Cash runway into Q3 2027 based on current operating plans
- ENTR-601-44 dystrophin increase 2.36% to total mean 6.36%
- ENTR-601-44 exon skipping increase 2.31% to total mean 4.97%
- Cohort 2 ENTR-601-44 topline results expected Q1 2027; ENTR-601-45 Cohort 1 data expected October 2026
Risk Factors
- No explicit new or changed risk factor identified; provided excerpt is a standard carried-forward disclosure
- Liquidity risk: cash, equivalents, and marketable securities expected to fund operations into third quarter of 2027
- Financing risk: $150.0 million at-the-market offering may not produce sales at acceptable prices
- Clinical concentration risk: ENTR-601-44 failure could diminish EEV Platform value and harm development plans
- Profitability risk: accumulated deficit reached $355.6 million as of June 30, 2026
AI summary of the TRDA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 references Entrada’s August 5, 2026 earnings press release
- Financial results and management commentary appear in Exhibit 99.1
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Entrada Therapeutics held its 2026 Annual Meeting virtually on June 10, 2026
- The filing’s Item 5.02 heading indicates director elections or officer appointments and compensation matters addressed at the meeting
Item 5.07: Submission of Matters to a Vote of Security Holders
- Annual meeting quorum established with 33,190,234 shares represented out of 38,820,616 outstanding
- Peter S. Kim and Bernhardt Zeiher elected Class II directors through the 2029 annual meeting
Item 7.01: Regulation FD Disclosure
- Corporate presentation dated May 2026 furnished under Regulation FD
- Investor-relevant disclosures likely contained in Exhibit 99.1 presentation
AI summaries of TRDA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TRDA
Don't miss the next TRDA filing
- Alerts as it files. A push when TRDA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TRDA, by share count.
- Ask anything. An AI agent that reads every TRDA filing and answers with sources.
TRDA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MPM BioVentures 2014, L.P. | Sell | Sep 9, 2026 | 28,837 | $7.13 |
| MPM BIOVENTURES 2018, L.P. | Sell | Sep 9, 2026 | 28,837 | $7.13 |
| MPM BioVentures 2014, L.P. | Sell | Sep 8, 2026 | 192,500 | $7.41 |
| MPM BIOVENTURES 2018, L.P. | Sell | Sep 8, 2026 | 192,500 | $7.41 |
| MPM BIOVENTURES 2018, L.P. | Sell | Sep 4, 2026 | 38,500 | $7.11 |
| MPM BioVentures 2014, L.P. | Sell | Sep 4, 2026 | 38,500 | $7.11 |
| MPM BioVentures 2014, L.P. | Sell | Sep 3, 2026 | 32,263 | $7.17 |
| MPM BIOVENTURES 2018, L.P. | Sell | Sep 3, 2026 | 32,263 | $7.17 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $129.0M | $210.8M | $25.4M |
| Operating Income | -$3.2M | $47.0M | -$157.9M |
| Net Income | -$6.7M | $65.6M | -$143.8M |
| Op. Margin | -2.5% | 22.3% | -621.1% |
| Net Margin | -5.2% | 31.1% | -565.5% |
| Balance Sheet | |||
| Total Assets | - | $526.3M | $377.4M |
| Equity | - | $428.7M | $306.1M |
| ROE | - | 15.3% | -47.0% |
| Per Share | |||
| EPS | - | $1.68 | $-3.47 |
| Cash Flow | |||
| Operating CF | $139.8M | -$41.6M | -$128.5M |
| CapEx | - | $3.2M | $1.0M |
Source: XBRL data in Entrada Therapeutics, Inc. (TRDA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TRDA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $80.8M |
| Q1 2026 | 26 | $91.7M |
| Q4 2025 | 23 | $73.6M |
| Q3 2025 | 23 | $48.3M |
| Q2 2025 | 22 | $61.3M |
| Q1 2025 | 19 | $43.0M |
| Q4 2024 | 16 | $76.6M |
| Q3 2024 | 13 | $21.6M |
- AQR Capital Management+620.0K (+780%)
- JPMorgan Chase & Co+481.6K (+3244%)
- Millennium Management+244.6K (+47%)
- BlackRock+224.5K (+10%)
- Citadel Advisors LLC+179.3K (+83%)
- D.E. Shaw & Co−46.6K (-59%)
- Goldman Sachs Group−35.4K (-17%)
- FMR LLC (Fidelity)−14.8K (-87%)
- Renaissance Technologies LLC−11.1K (-5%)
- PNC Financial Services−6 (-1%)
- Merck & Co.+1.74M
- Franklin Resources−11.1K
- U.S. Bancorp−70
Source: 13F-HR filings on SEC EDGAR (aggregated from 167 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TRDA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 10, 2026 | - | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
TRDA SEC filings: frequently asked questions
Are TRDA insiders buying or selling?
In the last 90 days, Entrada Therapeutics, Inc. (TRDA) officers, directors and 10% owners reported no open-market purchases and 33 open-market sales worth $10.3 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TRDA stock?
As of June 30, 2026, the largest Entrada Therapeutics, Inc. (TRDA) holders among the 13F filers tracked by SignalX were BlackRock ($19.0 million), Merck & Co. ($12.8 million), Vanguard Capital Management LLC ($9.3 million), Millennium Management ($5.6 million), AQR Capital Management ($5.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TRDA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Entrada Therapeutics, Inc. (TRDA) reported revenue of $25.4 million (down 87.9% from FY2024) and a net loss of $143.8 million. Diluted EPS was -$3.47. The figures come from the XBRL data in the 10-K.
What did TRDA report in its latest 8-K?
Entrada Therapeutics, Inc. (TRDA) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Item 2.02 references Entrada’s August 5, 2026 earnings press release.
What are the latest TRDA SEC filings?
Entrada Therapeutics, Inc. (TRDA) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on September 9, 2026.
What is TRDA's SEC CIK number?
Entrada Therapeutics, Inc. (TRDA)'s SEC Central Index Key (CIK) is 1689375. EDGAR lists every TRDA filing under that number.
Ask anything about TRDA
The research agent reads TRDA's filings, financials, insider trades and 13F holders, then answers with sources.